Every Form 4 that Zimmer Biomet (ZBH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBH filings page.
Desai Chintan reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. reported an equity award to executive Chintan Desai, President, APAC. On August 3, 2026, he received 10,168 restricted stock units (RSUs), each representing a contingent right to one share of common stock. One-third of the RSUs vest on each of August 3, 2027, 2028 and 2029, and following this award he holds 10,168 RSUs of this type.
ZIMMER BIOMET HOLDINGS executive Kevin R. Thornal exercised 9,957 Restricted Stock Units into 9,957 shares of common stock on August 1, 2026. To satisfy tax obligations on this RSU vesting, 4,266 shares were withheld at $92.68 per share. Following the transaction, Thornal held 19,913 RSUs, with the remaining units scheduled to vest half on August 1, 2027 and half on August 1, 2028.
Hilado Maria Teresa reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Maria Teresa Hilado received a grant of 389.498 Phantom Stock Units. These units track the value of Zimmer Biomet common stock on a 1-for-1 basis but are settled in cash, not shares.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors. Following this award, Hilado now holds a total of 12,983.867 Phantom Stock Units. Settlement is scheduled in ten annual cash installments after her service as a director ends.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of phantom stock units as part of board compensation. On the reported date, he acquired 180.323 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his balance to 2,990.182 units.
Each phantom stock unit is linked 1-for-1 to a share of Zimmer Biomet common stock and is scheduled to be settled in company shares within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Robert Hagemann received a grant of 317.369 Phantom Stock Units, equivalent on a 1-for-1 basis to shares of common stock. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are settled only in cash.
After this award, Hagemann holds a total of 33,269.443 Phantom Stock Units. The units will be paid out in five annual cash installments that begin within sixty days after the calendar year in which his service as a director ends, linking this compensation to his board tenure rather than near-term market trading.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 317.369 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is linked 1-for-1 to a share of common stock but will be settled in cash, not stock.
After this award, Higgins holds a total of 37,674.691 Phantom Stock Units on a direct basis. These units are scheduled to be paid out in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which his service as a director ends.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Sreelakshmi Kolli received a grant of 180.323 phantom stock units as a compensation award under the company’s deferred compensation plan for non-employee directors. Following this grant, she holds a total of 6,842.604 phantom stock units, which will be settled in common stock within sixty days after her board service ends.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell received a grant of 432.776 phantom stock units on June 30, 2026. These units are credited under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 rate with common stock and are to be settled in cash after his board service ends. Following this award, Farrell holds a total of 19,606.716 phantom stock units, reflecting routine, cash-settled director compensation rather than any open-market trading.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Louis Shapiro reported receiving a grant of phantom stock units as part of his non-employee director compensation. He was awarded 158.684 phantom stock units tied to company common stock on a 1-for-1 basis, bringing his total phantom stock holdings to 3,703.100 units. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in shares of Zimmer Biomet common stock within sixty days after he ceases serving as a director.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. officer Noor Jehanzeb received a grant of 1,857 Restricted Stock Units, each representing a right to one share of common stock. These RSUs vest over three years in equal one-third installments starting on June 1, 2027. After this award, Jehanzeb holds 1,857 RSUs directly.
ZIMMER BIOMET HOLDINGS, INC. executive Yi Sang, Group President, Asia Pacific, reported selling a total of 5,000 shares of Common Stock in open-market transactions on May 29, 2026 at prices around $82.65 per share. After these sales, he continues to hold a substantial direct position of over 27,000 shares.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Michael J. Farrell received new equity-based awards as part of his board compensation. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units tied to common stock, bringing his total Restricted Stock Units to 13,757.
On the same date, he also received 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his phantom unit balance to 19,173.940. These units are generally settled in shares of common stock after his board service ends and are subject to mandatory deferral and dividend reinvestment features.
BERNARD BETSY J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Betsy J. Bernard received equity-based compensation rather than trading shares in the market. She was granted 1,517.274 Restricted Stock Units and 875.350 Phantom Stock Units, each representing 1-for-1 rights to common stock.
The Restricted Stock Units are immediately 100% vested but must be deferred until the later of her board departure or three years after grant. The Phantom Stock Units, accrued under the Deferred Compensation Plan for Non-Employee Directors, will be settled in common shares within sixty days after her service as a director ends. Following these awards, her reported holdings rose to 24,506 Restricted Stock Units and 21,581.562 Phantom Stock Units.
Zimmer Biomet director Maria Teresa Hilado received new equity awards as part of her board compensation. On May 22, 2026, she was granted 1,517.274 Restricted Stock Units tied to common stock, bringing her total Restricted Stock Units holdings to 9,098. These units are immediately 100% vested but are subject to mandatory deferral until the later of her termination of service as a director or three years after the grant date.
She was also granted 875.350 Phantom Stock Units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, increasing her phantom stock balance to 12,594.369 units. The phantom units convert 1-for-1 into company common stock and are to be settled in shares within sixty days after she ceases serving as a director. The phantom balance includes 34.300 units accrued on April 30, 2026 through a dividend reinvestment provision, and some Restricted Stock Units granted in prior years remain subject to different mandatory deferral periods.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Louis Shapiro received new equity-based awards. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units tied to common stock, increasing his total Restricted Stock Units to 3,991.063.
He was also granted 875.350 Phantom Stock Units under the Zimmer Biomet Deferred Compensation Plan for Non-Employee Directors, bringing his total phantom units to 3,544.416, including 7.812 units accrued through dividend reinvestment. Both award types represent deferred compensation, with phantom units and deferred RSUs to be settled in company common stock under the plan’s terms.
Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Devdatt Kurdikar received new equity-based awards as part of director compensation. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units, each representing one share of common stock, bringing his RSU holdings to 2,922.072 units. He also received 875.350 Phantom Stock Units under the Deferred Compensation Plan, increasing his phantom unit balance to 2,809.859 units. The phantom units are credited 1-for-1 in common stock and are to be settled in shares within sixty days after his service as a director ends. The RSUs are immediately 100% vested but are subject to mandatory deferral, generally until at least three years after grant and his termination of board service. These are compensation-related grants rather than open-market purchases or sales.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Sreelakshmi Kolli received equity-based compensation in the form of derivative awards. On May 22, 2026, Kolli was granted 1,517.274 Restricted Stock Units tied to Zimmer Biomet common stock, increasing her directly held RSUs to 6,875.
On the same date, she was also granted 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, bringing her phantom unit balance to 6,662.281. These phantom units are credited on a 1-for-1 basis with Zimmer Biomet common shares and are to be settled in shares of common stock within sixty days after her service as a director ends.
The RSUs are immediately 100% vested but are subject to mandatory deferral until the later of her termination of service as a director or three years after the grant date. Some units and RSUs referenced include amounts accumulated earlier through the plan’s dividend reinvestment and prior-year grants subject to different deferral periods.
Jafry Syed A. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Syed A. Jafry reported compensation-related equity awards. He received 1,517.274 Restricted Stock Units tied to common stock and 875.350 Phantom Stock Units, each representing a 1-for-1 right to receive one share of common stock.
The Restricted Stock Units are immediately 100% vested but are subject to mandatory deferral until the later of the end of his board service or three years after the grant date. The Phantom Stock Units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in shares within sixty days after he ceases to serve as a director.
Zimmer Biomet director Arthur J. Higgins received new equity-based compensation awards. He was granted 1,517.274 Restricted Stock Units tied to common stock, bringing his Restricted Stock Unit holdings to 26,382 units. He also received 875.350 Phantom Stock Units under the Deferred Compensation Plan, increasing his phantom unit balance to 37,357.322 units.
The phantom units have a 1-for-1 conversion ratio into common stock and are to be settled in shares within sixty days after he ceases serving as a director. The Restricted Stock Units are immediately 100% vested but are subject to mandatory deferral until the later of his termination of service as a director or three years after the grant date, and include prior-year grants with different deferral periods.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Robert Hagemann received equity-based compensation rather than buying shares on the market. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units, all immediately vested but subject to mandatory deferral until at least three years after the grant or his board service ends.
He was also credited with 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, bringing his phantom unit balance to 32,952.074 units. These phantom units track common stock 1-for-1 and will be settled in shares within sixty days after he ceases serving as a director. Following the RSU grant, he holds 25,927 Restricted Stock Units in total, including prior awards with different deferral periods.
Stellato Paul A reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received a grant of 9,232 Restricted Stock Units on May 1, 2026. Each unit represents a contingent right to receive one share of the company’s common stock.
The award vests annually over three years in equal one‑third installments, beginning on May 1, 2027. Following this grant, Stellato holds 9,232 Restricted Stock Units directly, reflecting a routine equity-based compensation award rather than an open-market stock purchase or sale.
Zimmer Biomet Holdings executive Noor Jehanzeb reported the vesting and exercise of 6,626 restricted stock units (RSUs) into the same number of shares of common stock on April 1, 2026. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock.
To cover tax obligations on this vesting, 1,677 shares of common stock were withheld by the company at a value of $90.67 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Jehanzeb directly holds 5,151 shares of common stock, which include 202 shares previously acquired under the Employee Stock Purchase Plan, and 13,249 RSUs that continue to vest, with one-third vesting on April 1, 2026 and the remaining RSUs vesting in two equal installments on April 1, 2027 and April 1, 2028.
Jafry Syed A. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Syed A. Jafry received 182.421 phantom stock units as a compensation award. These units were granted under the Zimmer Biomet Deferred Compensation Plan for Non-Employee Directors and are convertible into an equal number of common shares on a 1-for-1 basis. Following this award, Jafry holds a total of 7,391.591 phantom stock units, which are to be settled in company common stock within sixty days after his service as a director ends.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Kolli Sreelakshmi received a grant of phantom stock units as director compensation. On March 31, 2026, she was awarded 175.404 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, tied 1-for-1 to common stock. These units are to be settled in shares of company common stock within sixty days after she ceases serving as a director. Following this award and prior dividend reinvestments, she now holds a total of 5,769.994 phantom stock units, including 15.067 units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Louis Shapiro received a grant of 154.356 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors. These units are a form of deferred equity-based compensation rather than a cash payment.
The award brings his total Phantom Stock Units to 2,661.254, each convertible into one share of common stock on a 1-for-1 basis. The units will be settled in company common stock within sixty days after his service as a director ends, and the total includes 6.544 units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Maria Teresa Hilado received a grant of phantom stock units as part of her non-employee director compensation. She acquired 378.873 phantom stock units tied on a 1-for-1 basis to common stock value, bringing her total phantom stock units to 11,684.719.
These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash through ten annual installments starting within sixty days after the calendar year in which her board service ends. The total includes 30.381 units added earlier through the plan’s dividend reinvestment provision.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 308.711 Phantom Stock Units on March 31, 2026 under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible on a 1-for-1 basis with common stock but is to be settled in cash.
The units are scheduled to be paid in ten annual installments, beginning within sixty days after the end of the calendar year in which Higgins’ service as a director ends. Following this award and prior accruals, including 99.385 units from dividend reinvestment on January 30, 2026, he holds 36,375.195 phantom stock units.
Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of 154.356 Phantom Stock Units, each tied 1-for-1 to common shares. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors at a stated price of $0.0000 per unit.
Following this award, Kurdikar holds a total of 1,928.847 Phantom Stock Units. The units, including 4.508 accrued through dividend reinvestment on January 30, 2026, are scheduled to be settled in shares of Zimmer Biomet common stock within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Robert Hagemann reported receiving a grant of 308.711 Phantom Stock Units on March 31, 2026. These units are tied 1-for-1 to the company’s common stock value and increase his deferred balance to 31,982.841 units.
The units were accrued under Zimmer Biomet’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash in five annual installments after his board service ends. His balance also includes 87.178 phantom units added earlier under the plan’s dividend reinvestment provision.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell reported an award of phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors. He received 420.97 phantom stock units tied on a 1-for-1 basis to common stock, bringing his total phantom stock holdings to 18,245.033 units.
The phantom stock units are cash-settled in a lump sum within sixty days after he ceases serving as a director. His total includes 48.381 phantom stock units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an open-market sale of company stock. She sold 2,650 shares of common stock at an average price of $94.66 per share. After this transaction, she directly holds 10,224 shares of Zimmer Biomet common stock.
Zimmer Biomet Holdings Exec VP & CFO Suketu Upadhyay exercised restricted stock units into 14,776 shares of common stock on March 6, 2026. To cover tax obligations on this RSU vesting, 6,576 shares were withheld by the company at $92.54 per share. After these compensation-related transactions, Upadhyay directly holds 69,485 shares of Zimmer Biomet common stock.
Zimmer Biomet Holdings, Inc. Group President EMEA Wilfred Van Zuilen exercised restricted stock units on March 6, 2026, converting 7,004 RSUs into common shares. The company withheld 1,822 shares at $92.54 per share to cover tax obligations, leaving a net 5,182 shares. Following these compensation-related transactions, he directly holds 30,991 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity. On March 6, 2026, restricted stock units converted into 5,634 shares of common stock, with each RSU representing one share.
To cover tax withholding obligations on the RSU vesting, the company withheld 2,178 shares at a reference price of $92.54 per share, as disclosed. After these transactions, Winkler directly owns 12,874 shares of Zimmer Biomet common stock. The filing shows no open‑market purchases or sales, only RSU vesting and tax withholding.
Zimmer Biomet Holdings executive Yi Sang, Group President, Asia Pacific, reported the exercise and conversion of restricted stock units into common stock. On March 6, 2026, he exercised a total of 9,414 restricted stock units, receiving an equal number of common shares.
Following these transactions, Yi Sang directly owned 32,251 shares of common stock. The restricted stock units converted at no cash exercise price, reflecting the vesting of equity-based compensation rather than open-market purchases or sales.
ZIMMER BIOMET HOLDINGS, INC. executive Paul A. Stellato, VP, Controller and Chief Accounting Officer, reported routine equity compensation activity. On March 6, 2026, restricted stock units covering 1,363 shares and 607 shares were converted into the same number of shares of common stock.
To cover related tax withholding on these vestings, the company retained 633 shares and 282 shares of common stock at $92.54 per share, as described in the footnotes. After these transactions, Stellato directly held 5,582 shares of Zimmer Biomet common stock.
ZIMMER BIOMET HOLDINGS, INC. executive Chad F. Phipps exercised restricted stock units into common stock and used a portion of the resulting shares to cover taxes. On March 6, 2026, RSUs representing 6,786 shares of common stock were converted.
The company withheld a total of 2,732 shares of common stock at $92.54 per share to satisfy tax withholding obligations, as disclosed in the footnotes. After these transactions, Phipps directly owned 67,760 shares of Zimmer Biomet common stock. These events reflect compensation-related vesting and tax withholding rather than open-market trading.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos exercised restricted stock units into 34,704 shares of common stock on March 6, 2026. The company withheld 19,195 shares at $92.54 per share to cover tax obligations, leaving him with 83,191 shares held directly.
Zimmer Biomet Holdings executive Wilfred Van Zuilen reported equity compensation activity involving restricted stock units and common shares. On February 25, 2026, he exercised 3,182 restricted stock units at $0.00 per unit, resulting in 3,182 shares of common stock acquired and increasing his direct common stock holdings to 26,637 shares before tax withholding.
As part of the same vesting event, 828 common shares valued at $99.51 per share were withheld by the company to cover tax obligations, leaving him with 25,809 directly held common shares. One-third of the restricted stock units vested on February 25, 2026, with the remaining units scheduled to vest in equal parts on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings, Inc. executive Chad F. Phipps reported routine equity compensation activity. On February 25, 2026, 2,626 restricted stock units were converted into an equal number of common shares at no cash exercise price as part of a scheduled vesting.
To cover tax withholding on the RSU vesting, 1,057 common shares were withheld by the company at a price of 99.51 per share, as noted in the footnotes. After these transactions, Phipps directly owned 63,706 shares of common stock and 5,249 restricted stock units.
Zimmer Biomet Holdings executive Yi Sang reported an equity award vesting and conversion. On February 25, 2026, 2,785 restricted stock units were exercised and converted into 2,785 shares of common stock at a stated price of $0.00 per share.
Following these transactions, Yi Sang directly held 5,567 restricted stock units and 22,837 shares of common stock. According to the vesting schedule, one-third of the RSUs vested on February 25, 2026, with the remaining units vesting one-half on each of February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported equity transactions tied to restricted stock units. On February 25, 2026, 2,347 RSUs were exercised into 2,347 shares of common stock at $0.00 per share as part of an RSU vesting event. A footnote explains that one-third of the RSUs vested on that date, with the remainder vesting in equal parts on February 25, 2027 and February 25, 2028. To cover tax withholding on the vesting, 924 shares of common stock were withheld by the company at a reference price of $99.51 per share. After these transactions, Winkler directly held 9,418 shares of common stock and 4,693 RSUs.
Zimmer Biomet Holdings' Executive VP and CFO Suketu Upadhyay reported equity award activity involving restricted stock units and common shares. On February 25, 2026, he exercised 6,364 restricted stock units, converting them into 6,364 shares of common stock at a stated price of $0.0000 per share. Following this conversion, his direct holdings increased to 64,117 shares of common stock and 12,726 restricted stock units. On the same date, 2,832 common shares at $99.51 per share were withheld by the company to satisfy tax withholding obligations linked to the RSU vesting, rather than an open-market sale.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos reported equity award activity involving restricted stock units and common shares of ZBH. He exercised or converted 19,090 restricted stock units into 19,090 shares of common stock at a price of $0.0000 per share. To cover tax withholding on the RSU vesting, 10,557 common shares were withheld by the company at a price of $99.5100 per share, as described in the footnotes. Following these transactions on February 25, 2026, his directly held common stock position was 67,682 shares, and 38,179 restricted stock units remained outstanding, with one-third vesting on February 25, 2026 and the balance vesting in equal installments on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings officer Paul A. Stellato reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 25, 2026, 820 RSUs were exercised and converted into 820 shares of common stock at a stated price of $0.0000 per share.
On the same date, 402 common shares were withheld at $99.5100 per share to cover tax withholding obligations related to the RSU vesting, as described in the footnotes. One-third of the RSUs vested on February 25, 2026, with the remaining RSUs scheduled to vest one-half on each of February 25, 2027 and February 25, 2028.
Following these transactions, Stellato directly held 1,638 RSUs and 4,527 shares of common stock. The disposition was for tax withholding rather than an open-market sale.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.
ZIMMER BIOMET HOLDINGS, INC. officer Chad F. Phipps reported equity compensation and related share movements. On February 20, 2026, 2,246 restricted stock units were exercised into 2,246 shares of common stock at a price of $0.00 per share.
He was also granted 9,818 new restricted stock units, each representing a right to receive one common share, vesting annually over three years in one‑third installments starting February 20, 2027. To satisfy tax withholding on the RSU vesting, 942 common shares were disposed of at $98.62 per share through company share withholding, leaving him with 62,137 directly held common shares.
Thornal Kevin R reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. reported that executive Kevin R. Thornal, Group President–Global Business, received a grant of 27,385 restricted stock units (RSUs) on February 20, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings executive Yi Sang reported equity awards and conversions, increasing his direct holdings through stock-based compensation. He acquired 2,382 shares of common stock on February 20, 2026 via exercise or conversion of restricted stock units (RSUs) at $0.00 per share, bringing his direct common stock ownership to 20,052 shares.
On the same date, he also acquired 2,382 RSUs through an exercise or conversion and received a new grant of 9,043 RSUs. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and vests annually over three years in one-third increments starting on February 20, 2027.
Zimmer Biomet Group Pres, EMEA Wilfred Van Zuilen reported equity compensation activity. On February 20, 2026, 2,451 restricted stock units vested into the same number of common shares, and 638 shares were withheld to cover tax obligations. He also received a new award of 10,334 restricted stock units that vest annually over three years starting February 20, 2027. After these transactions, he directly holds 12,784 restricted stock units and 23,455 shares of common stock.